Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
9-valent human papillomavirus vaccine + elasomeran
- Development stage
- Phase 3
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
9-valent human papillomavirus vaccine + elasomeran is a concomitant vaccination regimen consisting of the 9-valent recombinant human papillomavirus (HPV) vaccine (Gardasil 9) and the mRNA-1273 SARS-CoV-2 vaccine (elasomeran). Developed by Merck & Co. and Moderna, this regimen is being evaluated in Phase 3 clinical trials to assess the safety and immunogenicity of administering both vaccines together, particularly in children aged 9 to 11 years. The HPV component provides protection against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, which are associated with cervical cancer and other HPV-related diseases. The mRNA-1273 component is a nucleoside-modified messenger RNA vaccine that encodes the spike protein of the SARS-CoV-2 virus to prevent COVID-19. The study aims to facilitate healthcare delivery by reducing the number of visits required for adolescent immunization.
- Brand names
- Spikevax
- Other names
- 9vHPV + mRNA-1273Gardasil 9 + Spikevax
02
Targets
HPV L1 (Human papillomavirus L1 capsid protein)SARS-CoV-2 spikeHPV11 L1HPV16 (Human papillomavirus type 16)HPV18 L1HPV31 L1HPV33 L1HPV45 L1HPV52 L1 (Human papillomavirus type 52 major capsid protein L1)HPV58 L1 (Human papillomavirus type 58 major capsid protein L1)HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)
Beyond the preview
Go deeper on 9-valent human papillomavirus vaccine + elasomeran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 9-valent human papillomavirus vaccine + elasomeran.